This study aimed to compare the efficacy of different doses of
femoston with expectant management in patients with
incomplete abortions. Patients diagnosed with
incomplete abortion were included if they chose to continue medical treatment after relevant
contraindications were excluded. Participants were divided into 3 groups: the
femoston (1/10) and
femoston (2/10) groups received different doses of
femoston, and patients in the control group received expectant treatment. The success rate of complete abortion and the rate of menstrual recovery among the 3 groups were compared to evaluate the efficacy of different doses of
femoston in patients with
incomplete abortions. A total of 197 patients were analyzed: 73 in the
femoston (1/10) group, 73 in the
femoston (2/10) group, and 51 patients were followed up without treatment in the control group. The
femoston group was significantly more effective than the control group P < .0001). The adjusted odds ratio (OR) and 95% confidence interval (CI) were 3.103 and 1.153 to 8.350 (P = .025). The success rate of complete abortion in the
femoston (2/10) group was significantly higher than that in the
femoston (1/10) group (adjusted OR: 0.403, 95% CI: 0.145-1.118, P = .081). In addition, the rate of menstrual recovery in the
femoston group was significantly higher than that in the control group (P = .007), and the rate in the
femoston (2/10) group was also higher than the
femoston (1/10) group with statistically significant (P = .001).
Femoston is effective in treating
incomplete abortion, with femostons containing 2 mg
estrogen being more effective. Patients with
incomplete abortion are treated with
femoston, and menstrual recovery time may be shortened. Femostons may be a new option for pharmacological treatment of
incomplete abortions.